All Digests

June 28, 2026 3 stories

Sacred Eye Beauty Launches 30-Day Ritual with GHK-Cu Skin Magic Tablets, FDA 503B GLP-1 Exclusion Comment Deadline Closes Monday June 29, Regulatory Week Ahead: PCAC Testimony Cutoff and Medicare GLP-1 Bridge Launch

Sacred Eye Beauty 30-Day Ritual launches with GHK-Cu/PQQ/Methylene Blue; FDA 503B GLP-1 comment deadline June 29; regulatory week ahead Mon-Wed.

Read digest →

June 27, 2026 3 stories

STAT BIO 2026 Closing Wrap on AI Dominance and China Anxiety, UVA's Dr. Catherine Varney Will Not Prescribe BPC-157 or TB-500, Medscape: Unapproved Retatrutide Poison-Center Exposures Up 265% as 50+ Clinics Openly Advertise

STAT BIO 2026 wrap on AI + China; UVA Dr. Varney warns BPC-157/TB-500 evidence is animal-only; Medscape: retatrutide poison exposures up 265%.

Read digest →

June 26, 2026 7 stories

Sangamo Files Chapter 11 with Lilly $50M Stalking-Horse Bid, 18 Bioethics Experts Call Retatrutide Compassionate Use Unusual, ONVAX-01 Peptide Nanovaccine in Pancreatic Cancer, HIMS June 25% Rally on Novo 'Voluminous Partner' Label, Medicare GLP-1 Bridge 5 Days Out, Brain Peptides Alzheimer's Review

Sangamo Chapter 11 + Lilly $50M; 18 bioethics experts on retatrutide; ONVAX-01; HIMS rally; Medicare GLP-1 Bridge July 1; brain peptides Alzheimer's review.

Read digest →

June 25, 2026 4 stories

Senator Hassan Letter to RFK Jr Asks if Trump Is Retatrutide Patient, Lilly's First Public Statement, Rep. Lieu Suggests Terminal Illness, BIO 2026 Closes in San Diego

Hassan letter to RFK Jr on retatrutide compassionate use; Lilly's first statement; Lieu terminal-illness press conference; BIO 2026 wraps June 25.

Read digest →

June 24, 2026 5 stories

Lilly Halves €2.3B Alzey Germany Plant on Dynamic Manufacturer Rebate, White House Calls STAT Reporter Names Over Retatrutide Story, PCAC Oral Testimony Deadline June 30, ML-Discovered Anti-Pseudomonas AMPs

Lilly halves Alzey plant on German pricing reform; White House escalates retatrutide pushback; PCAC oral testimony deadline June 30; anti-Pseudomonas AMPs.

Read digest →

June 23, 2026 4 stories

STAT Breaks FDA-Lilly Retatrutide Compassionate-Use for Mystery 79-Year-Old, Elicio AMPLIFY-7P KRAS Vaccine Misses Phase 2 Primary, Hims & Hers Stock Above $30 on PCAC Catalyst, Medicare GLP-1 Bridge Launches July 1

STAT: FDA-Lilly retatrutide compassionate use for mystery 79-year-old; Elicio AMPLIFY-7P miss; Hims stock above $30 on PCAC; Medicare GLP-1 Bridge July 1.

Read digest →

June 22, 2026 6 stories

BIO 2026 Opens San Diego: BioArctic-Lilly $800M BrainTransporter Pact, Novo Wegovy MASH Approved in Japan, TGA Australia Peptide Compliance Crackdown, USTR Germany Section 301, AGA POWER Framework Revision, Indena-Chemi PDC Partnership

BIO 2026 Day 1 brings BioArctic-Lilly $800M BrainTransporter pact; Wegovy MASH approved in Japan; TGA peptide crackdown; USTR Germany 301; AGA POWER revision.

Read digest →

June 21, 2026 5 stories

CKYN GHK-Cu Skincare Launch June 20, JN GLP-1 Malnutrition Review June 20, Pfizer CFO Transition, Biogen Closes $5.6B Apellis Acquisition Adding Cyclic Peptide Pegcetacoplan, BIO 2026 Opens San Diego June 22

CKYN Complete GHK-Cu Protocol launch, JN GLP-1 malnutrition review, Pfizer CFO transition, Biogen completes $5.6B Apellis acquisition, BIO 2026 opens June 22.

Read digest →

June 20, 2026 7 stories

HLB RGN-259 SEER-3 Phase 3 Miss, NervGen NVG-291 RESTORE Phase 3 Mid-2026, EndoCyclic ENDO-205 IND Cleared for Endometriosis, Bachem CCO Transition, CROI 2026 GLP-1 + HIV, PharmTech Peptide Manufacturing Feature

HLB RGN-259 SEER-3 miss, NervGen NVG-291 RESTORE Phase 3 mid-2026, EndoCyclic ENDO-205 IND endometriosis, Bachem CCO, CROI GLP-1 in HIV.

Read digest →

June 19, 2026 10 stories

Marea MAR002 First-in-Class Anti-GHR Antibody Phase 1 at ENDO 2026, EMA Synthetic Peptide Guideline Effective, Pep2Tango PTT-A Tetra-Agonist Beats Tirzepatide, France Wegovy/Mounjaro Reimbursement Live, BU Sontha 60K-Patient GLP-1 Discontinuation Study, Italgel + GELITA Collagen Peptide Launches

Marea MAR002 anti-GHR Phase 1 at ENDO 2026, EMA synthetic peptide guideline effective, Pep2Tango PTT-A 19%, France Wegovy reimbursement, Sontha 60K GLP-1 data.

Read digest →

June 18, 2026 7 stories

CordenPharma's AmbioPharm Subsidiary $120M Aiken County Peptide Expansion, Barclays Lifts Hims & Hers PT $29→$39 on Peptide Catalyst, Frontiers Cell-Penetrating Peptide Diabetes Delivery Paper, PCAC + 503B Deadlines 11-12 Days Out, AHA/ACC First-Ever CKM Syndrome Guideline, Ohio State Board Peptide Compounding Guidance, Hanmi HM500197 First Peptide-Based Myostatin Inhibitor at ADA 2026

AmbioPharm $120M SC peptide expansion, Barclays raises Hims to $39, Frontiers CPP diabetes delivery, PCAC/503B 11-12 days, AHA/ACC CKM guideline, Ohio + Hanmi.

Read digest →

June 17, 2026 6 stories

D&D Pharmatech + LG AI Research Peptide AI Partnership, Bloomberg Businessweek Peptide Gold Rush Feature, UCSD Semaglutide Epigenetic Aging Nature Communications, Azitra Cosmetic Peptide BIO 2026, Annals of Oncology 41% GLP-1 Cancer Risk Cut, Alabama Board Bans Research-Grade Peptides

D&D + LG AI lifts D&D 17%, Bloomberg gold-rush, UCSD semaglutide aging slowdown, Azitra +87%, Annals 41% cancer cut, Alabama bans research peptides.

Read digest →

June 16, 2026 5 stories

MultiValent Biotherapies $27M Series A for Prostate Cancer PDC, Tirzepatide PNAS Nexus Real-World Beats Semaglutide, JAMA Viewpoint on Online Peptide Regulation Gap, Business Group on Health: 10% of Employers Plan to Drop GLP-1 in 2027

MVB-101 PSMA × FRα prostate PDC launches with $27M, PNAS Nexus tirzepatide vs semaglutide real-world, JAMA viewpoint on online peptides, employer GLP-1 drop.

Read digest →

June 15, 2026 5 stories

Entera EB613 Single-Tablet ENDO 2026 Matches Forteo, Rhythm Setmelanotide PWS + Hypothalamic Obesity + BBS, Crinetics Atumelnant Phase 2 CAH, Neurocrine Crenessity Pediatric 2-Year, 503B Window 14 Days

ENDO 2026 day 3: Entera EB613 single-tablet matches Forteo; Rhythm setmelanotide across PWS, AHO, BBS; Crinetics atumelnant CAH; Neurocrine Crenessity year 2.

Read digest →

June 14, 2026 5 stories

Crinetics Palsonify 2-Year OLE at ENDO 2026, GLP-1 Patients Walk 560 Fewer Steps, Semaglutide Cuts Fractures 15%, Ascendis TransCon CNP 2-Year ApproaCH, GLP-1s and Male Fertility

ENDO 2026 day 2: Crinetics Palsonify 2-yr OLE confirms acromegaly control; GLP-1 secondary effects on activity, fractures, fertility; TransCon CNP year 2.

Read digest →

June 13, 2026 5 stories

ENDO 2026 Opens in Chicago, Ascendis TransCon PTH 5-Year 82% Response, Crinetics Palsonify 2-Year OLE Sunday, Entera EB613 Oral PTH Late-Breaker, Rusfertide EHA 2026 Long-Term

ENDO 2026 opens with PTH peptide showdown (Ascendis 82% 5-yr, MBX canvuparatide, Entera EB613); Crinetics Palsonify 2-yr OLE Sunday; rusfertide EHA 2026.

Read digest →

June 12, 2026 5 stories

Camurus Oclaiz Second Manufacturing CRL, MBX Canvuparatide Phase 2 + 1-Year OLE Hit, AJMC GLP-1 Emerging Indications, Parabilis $670M IPO Debut, The Hill on MAHA Peptide Push

Camurus second CRL on Oclaiz, MBX canvuparatide Phase 2 + 1-yr data set up Q3 Phase 3, Parabilis breaks IPO record at $670M, AJMC quantifies GLP-1 indication creep.

Read digest →

June 11, 2026 5 stories

Wegovy Pill UK MHRA Approval Today, Novartis Del-Brax FSHD Biomarker Hit, Wegovy Pill UAE Launch, Moes Group GHK-Cu Private-Label Manufacturing

Novo Wegovy pill clears UK MHRA today, Novartis del-brax met FSHD biomarker primary, Wegovy pill launched UAE June 3, Moes Group enters GHK-Cu OEM.

Read digest →